Show summary Hide summary
Eli Lilly shares surged on May 27, 2026, following Bank of America’s price target increase to $1,251—signaling Wall Street confidence in the pharma giant’s obesity drug dominance. The upgrade reflects accelerating Mounjaro revenue growth and retatrutide‘s landmark clinical data, positioning LLY stock as a beneficiary of the expanding GLP-1 market through 2026 and beyond.
🔥 Quick Facts
- BofA raised price target to $1,251, implying 22% upside from recent trading levels near $1,023
- Mounjaro generated $8.7 billion in Q1 2026 revenue—a 125% year-over-year increase—outpacing analyst expectations
- Retatrutide, Lilly’s next-generation GLP-1, delivered 28% body weight loss in late-stage trials (announced May 21, 2026)
- Full-year 2026 revenue guidance: $80–$83 billion, representing 25% growth at the midpoint
- Lilly captures 60% of the global GLP-1 market, far outpacing competitors including Novo Nordisk
Why BofA’s Upgrade Signals a New Leg of Growth
Bank of America’s action on May 26, 2026, reflects three catalysts that have redefined investor expectations for Eli Lilly. First, obesity drug demand has exceeded consensus estimates—not by single digits, but by multiples. Mounjaro’s $8.7 billion quarter (announced April 30, 2026) was driven by 59% U.S. revenue growth alone, a remarkable pace considering current market saturation concerns elsewhere in healthcare. Second, retatrutide’s late-stage positive results (released May 21, 2026) prove that Lilly’s innovation pipeline extends well beyond its current flagship. Patients on the highest dose lost over 28% of body weight in 80 weeks—a differentiation point versus Novo Nordisk’s Wegovy and Lilly’s own Zepbound. Third, the expanded addressable market due to Medicare obesity coverage beginning July 2026 opens millions of new eligible patients, a structural tailwind analysts had underestimated.
Revenue Momentum: The Numbers Behind the Confidence
Mounjaro’s performance leaves little doubt about Eli Lilly’s market leadership. In Q1 2026, the drug contributed $8.7 billion in worldwide revenue—surpassing the previous consensus expectation of $7.26 billion. Breaking this down geographically: U.S. sales reached $4.2 billion, a 59% increase from the year-ago period, demonstrating sustained adoption among both diabetic and off-label weight-loss patients. International markets accounted for $4.5 billion, underscoring global demand.
Trump account app launches on Apple and Google stores, $1,000 deposit planned for July
Iran peace deal awaits Trump’s final approval as 60-day negotiations framework reached
| Metric | Q1 2026 Result | YoY Change |
| Mounjaro Worldwide Revenue | $8.7 billion | +125% |
| Mounjaro U.S. Revenue | $4.2 billion | +59% |
| Lilly Total Q1 Revenue | $19.8 billion | +56% |
| Full-Year 2026 Guidance (Midpoint) | $81.5 billion | +25% |
| Normalized EPS (Q1 2026) | $8.55 | vs. $6.79 consensus |
These figures reveal that Lilly is not merely riding a trend—it is defining the market. With Mounjaro representing an increasingly larger slice of total revenue, and retatrutide poised as the next blockbuster (potentially clearing FDA approval in late 2026), the company’s financial trajectory justifies analyst enthusiasm.
Retatrutide: The Next Innovation Wave
Beyond current sales, Lilly’s next-generation GLP-1/GIP/glucagon triple agonist retatrutide has emerged as a pivotal inflection point. On May 21, 2026, the company announced that retatrutide delivered 28% average body weight loss at the highest dose over 80 weeks in its SURMOUNT-4 trial—significantly higher than Mounjaro’s efficacy profile and positioning itself as a superior therapeutic option for severe obesity. Patients achieved weight reductions exceeding 70 pounds on average, a clinically meaningful outcome. The drug’s three-receptor mechanism of action—targeting GLP-1, GIP, and glucagon simultaneously—offers a pharmacological advantage competitors have struggled to replicate. Bank of America analysts have noted that retatrutide could generate $15 billion in annual revenue by 2029, contingent on swift FDA clearance expected in the second half of 2026.
“Lilly is also comparing tirzepatide and retatrutide directly and expects to have results from that study toward the end of 2026 or early 2027, which could provide a clearer picture of competitive positioning.”
— Research commentary, Time Magazine, May 21, 2026
Market Catalysts: Medicare Coverage and Competition
Beginning in July 2026, Medicare will cover obesity medications for beneficiaries with a BMI of 30 or higher and at least one weight-related condition. This policy shift unlocks an estimated 8 million additional eligible patients in the United States—a structural expansion of addressable market that previous analyst models underweighted. Mounjaro’s current penetration among Medicare-eligible patients remains modest, suggesting upside as insurance coverage removes cost barriers. Competitively, Novo Nordisk’s Wegovy and Zepbound (a licensed version of Novo’s semaglutide) maintain respectable market share, but Lilly has achieved 60% of the global GLP-1 market through Mounjaro’s superior efficacy, manufacturing scale, and supplier partnerships. The arrival of Foundayo (Lilly’s oral GLP-1, anticipated in late 2026) will further extend the company’s addressable audience by capturing patients who favor oral over injectable therapies.
Will the $1,251 Price Target Hold?
At $1,251, BofA’s target implies a price-to-earnings ratio of approximately 20–23x 2026 normalized earnings, a reasonable multiple for a high-growth pharmaceutical leader with 20%+ revenue growth and expanding gross margins. Downside risks remain: regulatory delays for retatrutide, pricing pressure from Medicare negotiations, or unexpected safety signals could constrain upside. Nevertheless, the confluence of Mounjaro’s blockbuster status, retatrutide’s clinical superiority, and Medicare reimbursement expansion creates a multi-year runway. The $1,251 target represents far more than speculation—it reflects a credible path to $130+ billion in pharmaceutical revenue by 2028 across Eli Lilly’s oncology, immunology, and obesity franchises combined.
What Should Investors Watch Next?
Over the next six months, three milestones will define whether BofA’s upgrade gains traction: (1) retatrutide’s FDA approval decision, expected in Q3 or Q4 2026; (2) second-quarter 2026 earnings results in July, which will reveal whether Mounjaro momentum persists amid industry headwinds; and (3) the Medicare obesity coverage rollout in July 2026, which should produce visible demand expansion. If Lilly delivers on all three fronts, the stock could re-rate higher, validating BofA’s confidence and potentially triggering further analyst upgrades. Conversely, any stumble on reimbursement or regulatory timelines could pressure valuation multiples, even as underlying fundamentals remain robust.
Sources
- Bank of America Securities — Price target upgrade to $1,251 (May 26, 2026)
- Eli Lilly Investor Relations — Q1 2026 earnings release and financial guidance (April 30, 2026); Retatrutide trial data (May 21, 2026)
- Reuters, CNBC, Yahoo Finance — Lilly earnings coverage and analyst consensus tracking
- Benzinga, Time Magazine — GLP-1 market analysis and clinical trial reporting
